Discover scalable, innovative therapies for obesity. Our next-gen NuSH treatments offer effective, convenient solutions to empower lasting weight loss. Learn more today!

Sep 24, 2024 · For patients receiving Metsera’s investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative weight loss at Day 57, or four weeks after the...

Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.

Jan 7, 2025 · Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some of its $215 million war chest to assess monthly dosing of the...

Nov 13, 2024 · The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097, which was linked to a 7.5% reduction in body weight over 36 days in a phase 1...

Jan 2, 2025 · For patients receiving Metsera’s investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative weight loss at Day 57, or four weeks after the final dose, the biotech said in today’s release.

Sep 24, 2024 · Five months after launching, Metsera is making waves with Phase I results for a long-acting GLP-1 injectable showing a 7.5% reduction in body weight at day 36. The biotech said the results were as good as or better than approved or other similar clinical-stage GLP-1 compounds out there now.

Sep 24, 2024 · Metsera's Phase 1 trial of MET-097, a long-acting GLP-1 receptor agonist, demonstrated a 7.5% reduction in body weight from baseline at day 36. The drug's 380-hour half-life suggests the possibility for once-monthly dosing without titration, offering a more convenient and scalable treatment option.

Jan 7, 2025 · Months after posting weight loss of 7.5 percent at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11 percent average body weight reduction at 12 weeks, with no plateau and a promising safety profile.

Sep 24, 2024 · Evidence from the trial has shown that participants experienced a body weight reduction of 7.5% at the 1.2 mg dosage after a 36-day period. Remarkably, this weight loss figure climbed to 8.1% after a longer follow-up period of 57 days post final dose, indicating a sustained pharmacodynamic effect.